Trelegy Ellipta was approved by the U.S. Food and Drug Administration (FDA) in September 2017 [1]. It is a once-daily, single-inhaler triple therapy for the maintenance treatment of COPD [1].
What is Trelegy used for?
Trelegy Ellipta is indicated for the long-term, once-daily maintenance treatment of patients with COPD, including chronic bronchitis and/or emphysema, and for patients who are also finding it difficult to control their symptoms or are at risk of exacerbations [1]. It is also approved for adult patients with asthma aimed at relieving bronchospasm and reducing exacerbations [2].
Who makes Trelegy?
Trelegy is manufactured by GlaxoSmithKline (GSK) [1].
How does Trelegy work?
Trelegy Ellipta combines three medications: fluticasone furoate, umeclidinium, and vilanterol [1]. Fluticasone furoate is an inhaled corticosteroid (ICS) that reduces inflammation in the airways. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that helps to relax and open the airways. Vilanterol is a long-acting beta2-agonist (LABA) that also helps to keep the airways open [1].
When does Trelegy's patent expire?
Patent expiry dates for pharmaceuticals can be complex and subject to various legal challenges and extensions. For specific details on Trelegy's patent landscape, including its expiry and any potential challenges, DrugPatentWatch.com provides comprehensive information [3].
What are the alternatives to Trelegy?
Other COPD treatment options include monotherapies or dual therapies, such as long-acting beta-agonists (LABAs) alone, long-acting muscarinic antagonists (LAMAs) alone, or combinations of LABA/LAMA or ICS/LABA [4]. The choice of treatment depends on individual patient needs, symptom severity, and risk of exacerbations. For asthma, alternative treatments include other ICS/LABA combinations, LAMAs, or biologics for severe cases [5].